| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1399-2406.2003.00063.X |
| P698 | PubMed publication ID | 14700015 |
| P50 | author | Christopher S. Kovacs | Q37840198 |
| P2093 | author name string | Pierre Chue | |
| P2860 | cites work | Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin | Q22250892 |
| Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial | Q27860743 | ||
| Prolactin levels and adverse events in patients treated with risperidone. | Q50535480 | ||
| Psychological distress in patients with hyperprolactinaemia. | Q51100469 | ||
| Postpartum hostility and prolactin. | Q51251202 | ||
| A clinical monitoring form for mood disorders. | Q51951720 | ||
| Prevalence and correlates of diabetes in national schizophrenia samples. | Q53506906 | ||
| Overweight and obesity in the United States: prevalence and trends, 1960-1994 | Q64133342 | ||
| Persistent tardive dyskinesia in bipolar patients | Q69878537 | ||
| Higher frequency of neuroleptic-induced dystonia in mania than in schizophrenia | Q69926625 | ||
| Neuroleptic malignant syndrome | Q72208162 | ||
| Tardive dyskinesia and the primary psychiatric diagnosis | Q72574513 | ||
| Antipsychotic drug treatment in first-episode mania: a 6-month longitudinal study | Q73495126 | ||
| Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol | Q73671567 | ||
| Prevalence of overweight and obesity in bipolar patients | Q73805994 | ||
| Depression and risk of heart failure among the elderly: a prospective community-based study | Q77570088 | ||
| Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study | Q77769452 | ||
| The unhealthy lifestyle of people with schizophrenia | Q77998173 | ||
| Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults | Q28131763 | ||
| Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance | Q28186874 | ||
| Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II) | Q28193306 | ||
| Obesity and the risk of heart failure | Q28216583 | ||
| Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group | Q29615228 | ||
| Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group | Q29617736 | ||
| Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction | Q29618673 | ||
| Prevalence of sexual dysfunction among newer antidepressants. | Q30309316 | ||
| Dropout rates in randomised antipsychotic drug trials | Q30684652 | ||
| Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study | Q31829404 | ||
| Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders | Q31980098 | ||
| Barriers to progress--the impact of tolerability problems | Q33181789 | ||
| Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial | Q33425402 | ||
| Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study | Q33899442 | ||
| Good tolerability equals good results: the patient's perspective | Q34392459 | ||
| Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases | Q34523758 | ||
| Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia | Q34583697 | ||
| Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. | Q34735182 | ||
| The role of prolactin in mammary carcinoma | Q35067253 | ||
| Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group | Q43507067 | ||
| UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. | Q43554872 | ||
| A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder | Q43592694 | ||
| Prevalence of obesity and weight change during treatment in patients with bipolar I disorder | Q43642752 | ||
| Risperidone added to clozapine: impact on serum prolactin levels. | Q43740999 | ||
| United Kingdom Prospective Diabetes Study, 30: diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risk factors. | Q43810405 | ||
| Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy | Q43846648 | ||
| Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia | Q43941571 | ||
| Olanzapine versus divalproex in the treatment of acute mania | Q44013092 | ||
| Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety | Q44045819 | ||
| Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study | Q44103185 | ||
| A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania | Q44168457 | ||
| An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients | Q44206750 | ||
| Obesity as a correlate of outcome in patients with bipolar I disorder | Q44265285 | ||
| The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. | Q44275522 | ||
| Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial | Q44299951 | ||
| Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial | Q44385585 | ||
| TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. | Q45244072 | ||
| Orlistat in the treatment of psychopharmacologically induced weight gain. | Q47224203 | ||
| Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults | Q47239330 | ||
| Olanzapine increases weight and serum triglyceride levels. | Q47252169 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | bipolar disorder | Q131755 |
| P304 | page(s) | 62-79 | |
| P577 | publication date | 2003-01-01 | |
| P1433 | published in | Bipolar Disorders | Q15716681 |
| P1476 | title | Safety and tolerability of atypical antipsychotics in patients with bipolar disorder: prevalence, monitoring and management | |
| P478 | volume | 5 Suppl 2 |
| Q89268927 | Adaptation and validation of the "tolerability and quality of life" (TOOL) questionnaire in Chinese bipolar patients |
| Q45035278 | Adverse events associated with psychotropic treatment in African American children and adolescents. |
| Q37827219 | Aripiprazole: a clinical review of its use for the treatment of anxiety disorders and anxiety as a comorbidity in mental illness |
| Q92206043 | Atypical antipsychotic monitoring in the Kilkenny Mental Health Services |
| Q92069888 | Atypical antipsychotic monitoring: A survey of patient knowledge and experience |
| Q37781370 | Atypical antipsychotic tolerability and switching strategies in bipolar disorder |
| Q36797200 | Atypical antipsychotics for the treatment of bipolar disorder: more shadows than lights |
| Q52656684 | Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. |
| Q36836740 | Differential diagnoses and management strategies in patients with schizophrenia and bipolar disorder |
| Q34516264 | Effects of a multimodal lifestyle intervention on body mass index in patients with bipolar disorder: a randomized controlled trial. |
| Q35143541 | Long-term treatment of bipolar disorder with a radioelectric asymmetric conveyor |
| Q36433993 | Long-term treatment with atypical antipsychotics and the risk of weight gain : a literature analysis |
| Q36545075 | Long-term use of atypical antipsychotics in bipolar disorder |
| Q36390846 | Olanzapine/fluoxetine combination for bipolar depression |
| Q39888212 | The return of fixed combinations in psychiatry: fluoxetine and olanzapine combination |
| Q37981271 | Treatment-emergent adverse events associated with atypical antipsychotics |
Search more.